Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer


NCT01556490

Interventional

Phase 3

Active, not recruiting
STOP-HCC
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Mar 31,2012
All
18 Years
N/A
526

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.